Catherine Flores,
Associate Professor
Department:
MD-NEUROLOGICAL SURGERY
Business Phone:
(352) 273-9000
Business Email:
catherine.flores@neurosurgery.ufl.edu
Teaching Profile
Courses Taught
2018,2020-2024
GMS6382 Special Topics in Immunology
2018,2023-2025
GMS7979 Advanced Research
2018,2024-2025
GMS7980 Research for Doctoral Dissertation
2016
GMS7794 Neuroscience Seminar
2021-2025
GMS6140 Principles of Immunology
2021
GMS6383 Current Topics in Immunotherapy
2022,2024
GMS6090 Research in Medical Sciences
2022,2024
GMS6905 Independent Studies in Medical Sciences
2023
GMS6971 Research for Master’s Thesis
2024
GMS6691 Special Topics in Cell Biology and Anatomy
Publications
Academic Articles
2024
Development of a murine laser interstitial thermotherapy system.
Neurosurgical focus.
57(5)
[DOI] 10.3171/2024.8.FOCUS24452.
[PMID] 39486063.
2024
In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy development.
Neuro-oncology.
26(11):1964-1980
[DOI] 10.1093/neuonc/noae131.
[PMID] 38990913.
2024
mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.
Genome medicine.
16(1)
[DOI] 10.1186/s13073-024-01281-z.
[PMID] 38268001.
2023
Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of α-synucleinopathy.
ACS chemical neuroscience.
14(2):235-245
[DOI] 10.1021/acschemneuro.2c00539.
[PMID] 36571847.
2023
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis.
Journal for immunotherapy of cancer.
11(2)
[DOI] 10.1136/jitc-2022-004805.
[PMID] 36750252.
2022
Is There a Role for Immunotherapy in Central Nervous System Cancers?
Hematology/oncology clinics of North America.
36(1):237-252
[DOI] 10.1016/j.hoc.2021.09.002.
[PMID] 34801163.
2022
The current landscape of immunotherapy for pediatric brain tumors.
Nature cancer.
3(1):11-24
[DOI] 10.1038/s43018-021-00319-0.
[PMID] 35121998.
2021
Brain stem gliomas and current landscape.
Journal of neuro-oncology.
151(1):21-28
[DOI] 10.1007/s11060-020-03655-w.
[PMID] 33398531.
2021
Considerations when treating high-grade pediatric glioma patients with immunotherapy.
Expert review of neurotherapeutics.
21(2):205-219
[DOI] 10.1080/14737175.2020.1855144.
[PMID] 33225764.
2021
Myelopoiesis during Solid Cancers and Strategies for Immunotherapy.
Cells.
10(5)
[DOI] 10.3390/cells10050968.
[PMID] 33919157.
2020
Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research.
26(21):5689-5700
[DOI] 10.1158/1078-0432.CCR-20-1065.
[PMID] 32788225.
2020
Ultrahigh-Performance Liquid Chromatography-High-Resolution Mass Spectrometry Metabolomics and Lipidomics Study of Stool from Transgenic Parkinson’s Disease Mice Following Immunotherapy.
Journal of proteome research.
19(1):424-431
[DOI] 10.1021/acs.jproteome.9b00605.
[PMID] 31713431.
2019
Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells.
Stem cells (Dayton, Ohio).
37(2):166-175
[DOI] 10.1002/stem.2933.
[PMID] 30353618.
2019
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Neuro-oncology.
21(6):730-741
[DOI] 10.1093/neuonc/noz015.
[PMID] 30668768.
2019
Quantitative characterization of 3D bioprinted structural elements under cell generated forces.
Nature communications.
10(1)
[DOI] 10.1038/s41467-019-10919-1.
[PMID] 31292444.
2019
RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.
Molecular therapy : the journal of the American Society of Gene Therapy.
27(4):837-849
[DOI] 10.1016/j.ymthe.2018.10.007.
[PMID] 30448196.
2018
Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
24(16):3955-3966
[DOI] 10.1158/1078-0432.CCR-17-3061.
[PMID] 29712687.
2018
Lin-CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade.
Nature communications.
9(1)
[DOI] 10.1038/s41467-018-06182-5.
[PMID] 30333482.
2017
Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.
Oncoimmunology.
6(1)
[DOI] 10.1080/2162402X.2016.1256527.
[PMID] 28197373.
2016
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
22(3):582-95
[DOI] 10.1158/1078-0432.CCR-15-0713.
[PMID] 26405194.
2015
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.
Journal for immunotherapy of cancer.
3
[DOI] 10.1186/s40425-015-0058-0.
[PMID] 25901285.
2015
Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.
Oncoimmunology.
4(3)
[PMID] 25949916.
2015
Rna Nanoparticle Vaccines Facilitate and Sustain Adoptive Cellular Therapy Targeting Pediatric Intracranial Malignancies
Pediatric Blood & Cancer.
62(2)
2014
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
Clinical cancer research : an official journal of the American Association for Cancer Research.
20(4):972-84
[DOI] 10.1158/1078-0432.CCR-13-0709.
[PMID] 24352643.
2013
A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.
Cancer immunology, immunotherapy : CII.
62(11):1649-62
[DOI] 10.1007/s00262-013-1464-0.
[PMID] 23982483.
2013
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
PloS one.
8(3)
[DOI] 10.1371/journal.pone.0059082.
[PMID] 23527092.
2012
Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer.
Journal of applied physiology (Bethesda, Md. : 1985).
113(2):263-72
[DOI] 10.1152/japplphysiol.01575.2011.
[PMID] 22604887.
2010
Voluntary running prevents progressive memory decline and increases adult hippocampal neurogenesis and growth factor expression after whole-brain irradiation.
Cancer research.
70(22):9329-38
[DOI] 10.1158/0008-5472.CAN-10-1854.
[PMID] 20884629.
Grants
Aug 2023
ACTIVE
Developmentally regulated antigens for immunologic targeting of pediatric brain tumors
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jun 2023
ACTIVE
Immunotherapy for Synucleinopathies: Can Gut Microbiota Affect Efficacy?
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Jan 2022
– Jun 2023
Understanding Major Immunological Mechanisms That Allow Therapy to Overcome Treatment Resistance in Refractory Pediatric Tumors
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via NATL PEDIATRIC CANCER FOU
Sep 2021
– Sep 2022
SRB Thank you – Flores
Role: Principal Investigator
Funding: ALEXS LEMONADE STAND FOUNDATION
Jul 2021
ACTIVE
F30 (Francis) Thymic PD-1 blockade mediates the anti-tumor immune response in pediatric high-grade glioma
Role: Other
Funding: NATL INST OF HLTH NCI
Jul 2021
ACTIVE
A consortium effort to translate therapies for neurological diseases via an immune-competent organotypic platform
Role: Principal Investigator
Funding: UNIV OF NORTH CAROLINA CHAPEL HILL
via NATL INST OF HLTH NCATS
Sep 2020
ACTIVE
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Oct 2019
– Mar 2021
The use of hematopoietic stem and progenitor cells to reverse treatment resistance to PD-1 blockade
Role: Principal Investigator
Funding: ALEXS LEMONADE STAND FOUNDATION
Sep 2019
– Aug 2022
Adoptive Cell Therapies and Translational Neuroimaging in Synucleinopathy: Implications for Dementia with Lewy Body and Parkinson's Disease
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Sep 2019
– Jun 2024
Hematopoietic stem cells overcome treatment resistance to adoptive cellular therapy against malignant gliomas
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2019
– Mar 2021
Engineering T cell metabolic fitness to treat pediatric brain tumors
Role: Co-Investigator
Funding: ST BALDRICKS FOUNDATION
Jan 2018
– Dec 2019
Enhancing efficacy of adoptive immunotherapy against DIPG using hematopoietic stem cells
Role: Principal Investigator
Funding: MULTIPLE SPONSORS
Jul 2017
– Jun 2019
FIorida Center for Brain Tumor Research (FCBTR)
Role: Project Manager
Funding: ACCELERATE BRAIN CANCER CURE
Jun 2017
– Oct 2019
Evaluating the use of hematopoietic stem cells in overcoming immunosuppression within the brain tumor microenvironment
Role: Principal Investigator
Funding: AMER BRAIN TUMOR ASSOCIATION
Jun 2017
– May 2018
Flores – ALFS Equipment Award
Role: Principal Investigator
Funding: ALEXS LEMONADE STAND FOUNDATION
May 2017
– Aug 2017
Pediatric Oncology Student Training (POST) Program
Role: Principal Investigator
Funding: ALEXS LEMONADE STAND FOUNDATION
Jul 2015
– Sep 2020
Novel role of hematopoietic stem cells in immunologic rejection of malignant pediatric brain tumors
Role: Principal Investigator
Funding: ALEXS LEMONADE STAND FOUNDATION
Jul 2013
– Jun 2021
Florida Center for Brain Tumor Research – Statewide Brain Tumor Registry Program at the McKnight Brain Institute
Role: Project Manager
Funding: FL DEPT OF HLTH
Contact Details
Phones:
- Business:
- (352) 273-9000
Emails:
- Business:
- catherine.flores@neurosurgery.ufl.edu
Addresses:
- Business Mailing:
-
PO BOX 100265
DEPARTMENT OF NEUROSURGERY
GAINESVILLE FL 326100265 - Business Street:
-
DEPARTMENT OF NEUROSURGERY
GAINESVILLE FL 32611